Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 48 clinical trials
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

(completed) is a non-randomised, non-comparative, open-label evaluation of the safety and tolerability of ETC-1922159 together with the bone protective treatment (denosumab) in patients with advanced or

conventional therapy
serum pregnancy test
neutrophil count
cancer
oxaliplatin
  • 6 views
  • 23 Apr, 2022
  • 5 locations
Initial Management of MRONJ Stages I and II a Clinical Trial With Detection of Salivary Biomarkers

Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication in patients receiving antiresorptive therapies, such as Bisphosphonates and Denosumab. It is defined by the presence

  • 0 views
  • 24 Feb, 2021
  • 1 location
Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

This study is to evaluate the efficacy and safety of JMT103 in the treatment of postmenopausal women with osteoporosis.

  • 0 views
  • 29 Jul, 2022
  • 1 location
The DENOCHARCOT Trial

The aim of the present trial is to assess the efficacy of treatment of acute Charcot foot in diabetes patients with Prolia on clinical relevant Outcomes in a randomized, double blind, placebo-controlled trial.

  • 0 views
  • 10 Aug, 2021
  • 8 locations
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

(SOC) TKI at 3 months post treatment and 2) without actionable mutations on standard of care therapy (chemotherapy/immunotherapy) treated with zoledronic acid or denosumab at the same time period.

lung carcinoma
targeted therapy
kinase inhibitor
metastasis
cancer chemotherapy
  • 1 views
  • 27 May, 2022
  • 1 location
Medication-related Osteonecrosis of the Jaw (MRONJ) Registry (MRONJ)

Approximately 500 patients will be included in this patient registry. Data collection includes demographics, clinical data of underlying disease and use of bisphosphonates, denosumab and

  • 250 views
  • 31 Jan, 2022
  • 14 locations
Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation (BAD)

Discontinuation of denosumab results in a rebound response of bone turnover markers, which rise above baseline at 3 months and remain elevated until reaching again baseline levels approximately

bisphosphonate
binosto 70mg effervescent tablet
risedronate
alendronate
denosumab
  • 28 views
  • 17 Mar, 2022
  • 1 location
Bone Density and Vascular Calcifications Evolution After Renal Transplant

The investigators project is based on: Assessment of bone architecture by high resolution peripheral scanner (HRpQCT) and bone densitometry (DEXA); The non-invasive detection of vascular calcifications (by abdominal CT scanner) and bone abnormalities associated with kidney transplantation, as well as the analysis of evolution over time; Longitudinal evaluation of nephrological …

  • 0 views
  • 24 May, 2022
  • 1 location